Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Summit Therapeutics Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 121 | 4 | 164 | +47 |
| Shares | 72.2M | 8.05M | 84.5M | +20.4M (+31.7%) |
| Value | $563.0M | $62.8M | $1.85B | +$1.35B (+269.5%) |
4 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (65)
Institutions that held Summit Therapeutics Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (18)
Institutions that held Summit Therapeutics Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Anson Funds Management LP | 941,908 | $7.35M |
| Federated Hermes, Inc. | 544,877 | $4.25M |
| Arrowstreet Capital, Limited Partnership | 141,680 | $1.10M |
| Pinpoint Asset Management Ltd | 120,746 | $941.8K |
| Simplex Trading, LLC | 114,647 | $894.0K |
| Squarepoint Ops LLC | 86,064 | $671.3K |
| Hudson Bay Capital Management LP | 75,000 | $585.0K |
| Brevan Howard Capital Management LP | 31,214 | $243.5K |
| Centiva Capital, LP | 29,225 | $228.0K |
| Paloma Partners Management Co | 28,400 | $221.5K |
| Boston Private Wealth LLC | 17,150 | $133.8K |
| Bayesian Capital Management, LP | 16,499 | $128.7K |
| Quinn Opportunity Partners LLC | 11,000 | $85.8K |
| SEI Investments Co | 10,396 | $81.1K |
| Catalyst Funds Management Pty Ltd | 6,900 | $53.8K |
| National Bank of Canada | 1,600 | $13.0K |
| Macquarie Group Ltd | 1,274 | $9.94K |
| Pacer Advisors, Inc. | 944 | $7.36K |
Not filed for Q3 2024 yet (4)
Institutions that held Summit Therapeutics Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 7,898,585 | $61.6M |
| Hoylecohen, LLC | 86,408 | $674.0K |
| Susquehanna Fundamental Investments, LLC | 67,378 | $525.5K |
| Bradley & Co. Private Wealth Management, LLC | 200 | $1.56K |